DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT06792422

ABSALON

RecruitingPhase 4

A Study Investigating Oral Semaglutide in People with Open-Angle Glaucoma

Additive Benefits of Semaglutide for Open-AngLe Glaucoma - an Opportunity for Neuroprotection

Asset

Semaglutide

Oral · GLP-1 agonist

Listed sites

1

Recruiting sites

1

Enrollment

126

estimated

Study population

—

Key I/E criterion

—

Primary endpoint

•Photopic negative response of the electroretinogram after 6 months

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06792422
Org study ID97669
Secondary ID2024-518510-87-00
Secondary IDNNF22OC0079544The Novo Nordisk Foundation

Timeline

Milestones

Study first posted2025-01-24actual
Last update posted2025-01-24actual
Study start2025-01estimated (month precision)
Primary completion2028-08estimated (month precision)
Study completion2028-12estimated (month precision)

Assets

Investigational agents

Semaglutide

Eligibility

Who can enroll

Minimum age45 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Ability to read and speak Danish
•45 years or older at the time of inclusion
•Visual acuity equal to or above 0.5 in the study eye
•Diagnosis of POAG with MD ≤ 16 dB with repeatable and reliable (false positive less than 15 %) VF loss measured by standard automated perimetry on at least one eye
•Receiving IOP-lowering glaucoma treatment
•Nerve fiber layer defects identified by OCT

Exclusion criteria

•Diabetes or renal impairment
•Medical history of significant eye disease (including ocular trauma) other than glaucoma
•Ocular inflammation/infection within three months from inclusion
•Intraocular surgery 3 months before inclusion
•Smoker at the time of inclusion
•Pregnant or breast-feeding
•Females of childbearing potential who are not using adequate contraceptive, which includes the following: Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, or transdermal, progestogen-only hormonal contraception associated with inhibition of ovulation: oral, injectable, or implantable; Intrauterine device (IUD); Intrauterine hormone-releasing system (IUS); Bilateral tubal occlusion; Vasectomised partner; Sexual abstinence
•Subjects allergic to drug ingredients administered during the trial
•Subjects with untreated severe systemic disease or malignancies
•Previous history of pancreatitis
•BMI < 18.5
•Subjects receiving treatment with: Dipeptidyl peptidase-4 inhibitors; Other GLP-1RAs; Insulin; Insulin analogues; Sulfonylurea; Systemic corticosteroids; Immunosuppressants

Endpoints (10)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other clinical outcomes
6
Patient-reported / QoL
2
Safety / tolerability / PK
1
Other (unclassified)
1

Patient-reported / QoL

2 endpoints
Secondary/protocol endpoint

Health-related quality of life (HRQoL)

Time frame:From baseline to month 6.

EQ-5D index

change from baseline, improvement

Secondary/protocol endpoint

Health-related quality of life (HRQoL)

Time frame:From baseline to month 6.

change from baseline, improvement

Safety / tolerability / PK

1 endpoint
Secondary/protocol endpoint

Number of treatment-related adverse events as assessed by CTCAE v5.0

Time frame:From baseline to month 6.

Treatment-emergent AEs (any)

event count, event

Other clinical outcomes

6 endpoints
Primary/protocol endpoint/low confidence

Photopic negative response of the electroretinogram after 6 months

Time frame:From baseline to month 6.

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Photopic negative response of the electroretinogram after 3 months

Time frame:From baseline to month 3.

change from baseline, improvement

Secondary/protocol endpoint

Pelli-Robson chart contrast sensitivity test

Time frame:From baseline to month 6.

change from baseline, improvement

Other/protocol endpoint

Optical coherence tomography (OCT), ring scan

Time frame:From baseline to month 6.

change from baseline, improvement

Other/protocol endpoint

Optical coherence tomography (OCT), macular scan

Time frame:From baseline to month 6.

change from baseline, improvement

Other/protocol endpoint

Standard automated perimetry

Time frame:From baseline to month 6.

change from baseline, improvement

Other (unclassified)

1 endpoint
Other/protocol endpoint/low confidence

Multi-omics

Time frame:From baseline to month 6.

change from baseline, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.